GlassScriptPhysician profile
Jodie E Vogtman
NPI 1285656249
$8,761.35
in general payments reported to CMS, 2019-2025
33 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 92% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,093 · 2022: $1,596 · 2023: $1,549 · 2024: $3,283 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,758 · Travel and Lodging: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,757.61 |
| Travel and Lodging | $1,314.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,595.94 | 2021-2025 | |
| Nalu Medical, INC. | $1,785.82 | 2022-2024 | Nalu Neurostimulation System |
| Lundbeck LLC | $605.96 | 2023-2025 | Vyepti |
| Pfizer INC. | $541.08 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $507.26 | 2022-2025 | Xtampza, Belbuca |
| Averitas Pharma INC. | $359.05 | 2023-2025 | Qutenza |
| Ibsa Pharma INC. | $272.82 | 2021-2025 | Tirosint, Licart, Tirosint |
| Abbott Laboratories | $223.07 | 2022-2025 | Proclaim, Eterna, Octrode |
| Biohaven Pharmaceutical Holding Company LTD. | $221.67 | 2022 | |
| Grt US Holding, INC. | $207.95 | 2021-2022 | |
| Lilly USA, LLC | $162.84 | 2021-2023 | Emgality, Reyvow |
| Boston Scientific Corporation | $160.40 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceuticals, INC. | $146.50 | 2021 | |
| Pacira Therapeutics, INC. | $130.20 | 2021 | |
| Amgen INC. | $100.29 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $82.56 | 2022-2024 | Orthovisc, Monovisc |
| Nevro Corp. | $73.02 | 2023 | Senza |
| Vertos Medical, INC. | $69.00 | 2023-2024 | Mild Device Kit |
| Pacira Pharmaceuticals Incorporated | $65.90 | 2024-2025 | Zilretta, Iovera, Exparel |
| Vertex Pharmaceuticals Incorporated | $58.30 | 2024-2025 | |
| Si-Bone, INC. | $53.83 | 2022 | |
| Stryker Corporation | $43.50 | 2024 | Mild Device Kit |
| Bioventus LLC | $37.39 | 2022 | |
| Arbor Pharmaceuticals, INC. | $34.36 | 2021 | |
| Medtronic, INC. | $34.13 | 2021-2024 | Intellis Adaptivestim |
| Fidia Pharma USA INC. | $31.45 | 2022-2025 | Hymovis |
| International Rehabilitative Sciences, INC | $28.54 | 2024 | Rs 4i Plus Sequential Stimulator |
| Saluda Medical Americas, INC. | $28.35 | 2024 | Evoke |
| Avanos Medical | $24.78 | 2024 | Trivisc Sodium Hyaluronate |
| Curonix LLC | $22.74 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Globus Medical, INC. | $20.19 | 2025 | Vyrsa V1 |
| Scilex Pharmaceuticals INC. | $20.07 | 2021 | |
| Horizon Therapeutics Plc | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodie Vogtman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.